Inspire Medical Systems (NYSE:INSP) appointed Ezgi Tagci as vice president of investor relations, as of August 15, 2022.
Yagci brings over 15 years experience as an institutional investor in medical devices and healthcare services to the table. She’s also served in senior roles at top-tier investment firms like Balyasny Asset Management, Green Arrow Capital Management, Partner Fund Management and RS Investments. She holds both Masters and Bachelors degrees in Economics as well as a Bachelor of Arts in international relations, all from Boston University.
“The team is very excited to welcome Ezgi and her vast experience in the medical technology sector to Inspire. She will have a positive impact on our expanding investor relations program and play a key role in contributing to the overall strategy of the organization,” said Tim Herbert, president and chief executive officer of Inspire Medical Systems.
Inspire is a medical technology company focused on developing and commercializing minimally invasive options for patients suffering from obstructive sleep apnea. The company’s proprietary Inspire therapy is the first and only neurostimulation technology for moderate to severe obstructive sleep apnea that’s been approved by the Food and Drug Administration.
“I am thrilled to join the team at Inspire, especially as the company anticipates important product innovations and enhancements that will fuel its further growth. I look forward to contributing to Inspire’s mission of serving the many patients with untreated OSA,” said Yagci.
Yagci served as investor relations manager for Zimmer Biomet since July 2020 before making the jump. Her responsibilities included earnings preparation, investment conference participation, sell side interactions and shareholder outreach and engagement. Yagci was also responsible for the environmental, social and governance (ESG) disclosures and the company’s annual sustainability report.
This is coming on the heels of solid earnings from the company as sales beat analysts’ estimates by $13.3 million, riding a 73 per cent bump to close at $91.4 million. The company also reported a loss of $14.5 million, or 53 cents a share where the expectation from analysts indicated the company would lose 60 cents a share.
“The Inspire team executed extremely well during the second quarter, continuing the rebound from the first quarter that was challenged by both COVID and our normal seasonality. Moreover, our strong second quarter performance overcame several challenges common across the medical technology sector, including supply chain issues, staffing shortages and economic concerns, further highlighting the team’s resiliency and commitment to the patient,” said Tim Herbert, president and CEO of Inspire Medical Systems.
